Solving Genetic Diseases??? Dr. Neil Kumar, Founder & CEO, BridgeBio Pharma
07/03/24 • 23 min
This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases.
This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases.
Previous Episode
The Next Ozempic or Wegovy... But Without the Injection??? Dr. Steffen-Sebastian Bolz, CSO, Aphaia Pharma
What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.
Next Episode
A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology
This week on Biotech Nation, Dr. Marianne De Backer, CEO of Vir Biotechnology talks about their Phase 2 clinical trials targeting hepatitis B and D co-infections. Vir's approach uses two drugs: tobevibart (an antibody) and elebsiran (an siRNA). These drugs prevent the virus from entering liver cells and stop it from replicating. Preliminary results are promising, showing a significant reduction in viral RNA and normalization of liver enzyme levels. Dr. De Backer also highlights Vir's efforts in other infectious diseases and future plans.
BioTech Nation ... with Dr. Moira Gunn - Solving Genetic Diseases??? Dr. Neil Kumar, Founder & CEO, BridgeBio Pharma
Transcript
When I originally spoke with doctor Neil Kumar, the founder and CEO of Bridge Biopharma, he was very direct. Genetic diseases are solvable. Today, we'll hear from doctor Kumar about what he means and about the innovative corporate structure of Bridge BioPharma itself designed for innovation and success. Doctor Kumar, welcome back to the program.
Dr. Neil KumarThank you so much for having me again.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/biotech-nation-with-dr-moira-gunn-239455/solving-genetic-diseases-dr-neil-kumar-founder-and-ceo-bridgebio-pharm-59790937"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to solving genetic diseases??? dr. neil kumar, founder & ceo, bridgebio pharma on goodpods" style="width: 225px" /> </a>
Copy